PubMed Health⌕ Search

Biomedical subjects

D Shapira

Publications and source records attributed to D Shapira.

At least 19 recordsLinked to original sources
PubMed2003

Enhanced fusion-evaporation cross sections in neutron-rich 132Sn on 64Ni.

Evaporation residue cross sections have been measured with neutron-rich radioactive 132Sn beams on 64Ni in the vicinity of the Coulomb barrier. The average beam intensity was 2 x 10(4) particles per second and the smallest cross section measured was less than 5 mb. Large sub-barrier fusion enhancement was observed. Coupled-channel calculations taking into account inelastic excitation significantly underpredict the measured cross sections below the barrier. The presence of several neutron transfer channels with large positive Q values suggests that multinucleon transfer may play an important role in enhancing the fusion of 132Sn and 64Ni.

Journal Article↗
PubMed2003

Trapeziometacarpal joint osteoarthritis and carpal tunnel syndrome: a new surgical approach for concomitant treatment.

A new approach for the concomitant surgical treatment of trapeziometacarpal joint osteoarthritis and carpal tunnel syndrome through the same incision is described. The technique was used in 25 patients (20 women, five men; mean age, 56 years). At a mean follow-up of 27 months, there was complete disappearance of the symptoms of carpal tunnel syndrome in 20 of the 25 patients, incomplete but substantial relief in four patients, and no improvement in one patient. One patient had scar tenderness and another had a superficial wound infection. The surgical technique is simple, safe and cost-effective as it avoids separate operations for both pathologies. The procedure is not suitable for severe carpal tunnel syndrome or when direct visualization of the median nerve and the carpal tunnel is necessary.

Aged↗
PubMed2002

Nuclear fusion in collapsing bubbles-is it there? An attempt to repeat the observation of nuclear emissions from sonoluminescence.

We have repeated the experiment of Taleyarkhan et al. [Science 295, 1868 (2002)]] in an attempt to detect the emission of neutrons from d-d fusion during bubble collapse in deuterated acetone. Using the same cavitation apparatus, a more sophisticated data acquisition system, and a larger scintillator detector, we find no evidence for 2.5-MeV neutron emission correlated with sonoluminescence form collapsing bubbles. Any neutron emission that might occur is at least 4 orders of magnitude too small to explain the tritium production reported in Taleyarkhan et al. as being due to d-d fusion. We show that proper allowance for random coincidence rates in such experiments requires the simultaneous measurement of the count rates in the individual detectors.

Journal Article↗
PubMed2002

Coulomb excitation of radioactive 132,134,136Te beams and the low B(E2) of 136Te.

The B(E2;0(+)-->2+) values for the first 2+ excited states of neutron-rich 132,134,136Te have been measured using Coulomb excitation of radioactive ion beams. The B(E2) values obtained for 132,134Te are in excellent agreement with expectations based on the systematics of heavy stable Te isotopes, while that for 136Te is unexpectedly small. These results are discussed in terms of proton-neutron configuration mixing and shell-model calculations using realistic effective interactions.

Journal Article↗
PubMed2001

Decay of a Resonance in 18Ne by the Simultaneous Emission of Two Protons.

Radioactive ion beams of 17F were used to study several resonance states in 18Ne. Clear evidence for simultaneous two-proton emission from the 6.15 MeV state (Jpi = 1(-)) in 18Ne has been observed with the reaction 17F+1H. Because of limited angular coverage, the data did not differentiate between the two possible mechanisms of simultaneous decay, diproton (2He) emission or direct three-body decay. The two-proton partial width was found to be 21+/-3 eV assuming 2He emission and 57+/-6 eV assuming three-body decay. The total width of the 1(-) state was measured to be 50+/-5 keV. Several additional resonances that decay by single proton emission were also studied.

Journal Article↗
PubMed1993

Musculoskeletal manifestations of Crohn's disease.

The prevalence of musculoskeletal system complaint and involvement in a group of 54 Crohn's disease patients, with a follow-up of 2 to 40 years, was studied and compared to that of a control group of patients with a similar distribution of sex and age. Twenty-four (44%) with Crohn's disease complained of arthralgia in various joints, but only 7.4% had objective findings compatible with joint pathology such as swelling, tenderness, and decreased range of motion. None of them had any serological or radiological evidences of joint damage. No significant correlation was found between patients' complaints/physical signs and age, sex, duration, or severity of Crohn's disease or mode of medical or surgical treatment. In the control group, 46% complained of arthralgia in various joint. The differences in the percentages of arthralgia between the two groups was not significant, although they differed in location of the affected joint. In the Crohn's disease group, a significantly higher proportion of knee, hip, and wrist involvement was observed, while backache was very common in the control group. It is suggested that arthritis in patients with Crohn's disease is an uncommon finding and that arthralgia is just as prevalent as in a matched control group. The pathogenesis of arthralgia in such a condition may be caused by soft tissue involvement.

Adolescent↗
PubMed1991

[Sulfasalazine in rheumatoid arthritis].

Sulfasalazine (SLZ) is now a second-line treatment in rheumatoid arthritis (RA), as well as in psoriatic arthritis and ankylosing spondylitis. 54 patients with active RA were treated with enteric coated SLZ (2 g daily) in a 24-week open study. Clinical and laboratory parameters of disease activity were monitored initially and thereafter at 2-week intervals for the first 2 months, and then at 4-week intervals until the end of the 24-week study. There was significant clinical improvement at the end, as shown by scores for joint pain (Ritchie), grip strength and morning stiffness (p less than 0.0001, less than 0.0001 and less than 0.01, respectively, by paired t test). Clinical improvement was accompanied by significant decrease in erythrocyte sedimentation rate and increase in hemoglobin (p less than 0.002 and less than 0.016, respectively). There was improvement in some cases as early as 3 weeks after starting therapy. The drop-out rate was significant: 19/54 (35%), most (13) due to side-effects, mainly gastrointestinal; none of the side-effects were serious. Our results, similar to those of other studies, indicate that despite the high rate of side effects, SLZ is an effective, second-line drug for RA.

Arthritis, Rheumatoid↗